EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Pharmaceutical Industry Payments to Patient Groups in Australia: A Longitudinal Analysis of a Decade of Disclosures

Ashleigh Hooimeyer iD, Annim Mohammad iD, Alice Fabbri iD, Lisa Parker iD, Kellia Chiu iD, Barbara Mintzes iD

Medical Journal of Australia · 2026

DOI: 10.5694/mja2.70294 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medical Journal of Australia, 2026. Verfasst von Ashleigh Hooimeyer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Drug Industry, Disclosure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Education, Australian Government, Research Training Program Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To analyse the extent and patterns of pharmaceutical industry funding of patient groups in Australia between 2013 and 2022, including the proportion of groups' income derived from industry payments in 2022. Study Type Longitudinal observational study. Setting, Participants Australia, 1 January 2013–31 December 2022. Public disclosures of payments to patient groups from pharmaceutical companies who were members of Medicines Australia (the trade organisation for the prescription pharmaceutical industry in Australia) between 2013 and 2022 and from non‐member companies with at least five registered prescription products in Australia. Main Outcome Measures Value (in Australian dollars) of reported payments to patient groups from the pharmaceutical industry and trends in payments by clinical area and over time. For patient groups that received industry funding in 2022, we also examined how this compared with their total income for that year.

Results

Between 2013 and 2022, 45 pharmaceutical companies disclosed $95.7 million in funding to 390 patient groups. Funding was highly skewed, with 13 groups receiving 47.9% ($45,856,940/$95,724,493) of the total payments. The median funding over the decade was $34,374 (interquartile range [IQR], $8228–$122,898) per group. The total reported payments decreased by $293,246 (95% confidence interval, $125,489–$461,006) per year, but some clinical areas, such as oncology, saw an increase. For groups that received funding in 2022, the median proportion of income derived from industry was 2.2% (IQR, 0.3%–9.3%) and nine groups had over half their income from industry.

Conclusions

Industry funding of patient groups was widespread but skewed towards a small subset of groups and clinical areas. This may shift the focus of advocacy efforts towards certain conditions that align with current industry interests. Although further research is still needed on links between funding and patient group priorities, current disclosure measures may be insufficient to manage risks and access to other funding sources and additional safeguards may be needed to maintain independence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryDisclosureAustraliaHumansLongitudinal StudiesConflict of InterestIncome

Stichwörter der Autor:innen

advertising as topicdrug industryfinancial managementhealth policymedical economicssocial determinants of health

Autor:innen und Institutionen

  • Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, Sydney Pharmacy School, University of Sydney, Sydney, New South Wales, Australia.
  • Department for Health, University of Bath, Bath, UK.
  • Faculty of Medicine and Health, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Ashleigh Hooimeyer, Annim Mohammad, Alice Fabbri, Lisa Parker, Kellia Chiu, Barbara Mintzes

Förderung

  • Department of Education, Australian Government, Research Training Program Scholarship

Zitieren

APA

Hooimeyer, A., Mohammad, A., Fabbri, A., Parker, L., Chiu, K., & Mintzes, B. (2026). Pharmaceutical Industry Payments to Patient Groups in Australia: A Longitudinal Analysis of a Decade of Disclosures. Medical Journal of Australia. https://doi.org/10.5694/mja2.70294

Vancouver

Hooimeyer A, Mohammad A, Fabbri A, Parker L, Chiu K, Mintzes B. Pharmaceutical Industry Payments to Patient Groups in Australia: A Longitudinal Analysis of a Decade of Disclosures. Medical Journal of Australia. 2026. doi:10.5694/mja2.70294

BibTeX
@article{Hooimeyer2026,
  author = {Hooimeyer, Ashleigh and Mohammad, Annim and Fabbri, Alice and Parker, Lisa and Chiu, Kellia and Mintzes, Barbara},
  title = {Pharmaceutical Industry Payments to Patient Groups in Australia: A Longitudinal Analysis of a Decade of Disclosures},
  journal = {Medical Journal of Australia},
  year = {2026},
  doi = {10.5694/mja2.70294}
}
Kostenlos starten →